Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 19;59(43):18885-18897.
doi: 10.1002/anie.202008319. Epub 2020 Sep 2.

Current Status of COVID-19 (Pre)Clinical Vaccine Development

Tingting Ye  1 , Zifu Zhong  1 , Adolfo García-Sastre  2   3   4   5 , Michael Schotsaert  2   3 , Bruno G De Geest  1
Affiliations
Review

Current Status of COVID-19 (Pre)Clinical Vaccine Development

Tingting Ye et al. Angew Chem Int Ed Engl. .

Abstract

The current COVID-19 pandemic has a tremendous impact on daily life world-wide. Despite the ability to dampen the spread of SARS-CoV-2, the causative agent of the diseases, through restrictive interventions, it is believed that only effective vaccines will provide sufficient control over the disease and revert societal live back to normal. At present, a double-digit number of efforts are devoted to the development of a vaccine against COVID-19. Here, we provide an overview of these (pre)clinical efforts and provide background information on the technologies behind these vaccines. In addition, we discuss potential hurdles that need to be addressed prior to mass scale clinical translation of successful vaccine candidates.

Keywords: COVID-19; SARS-CoV-2; pandemic; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic overview of the different types of vaccines.
Figure 2
Figure 2
Schematic illustration of the SARS‐CoV‐2 virus structure.
See this image and copyright information in PMC

References

    1. Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W., Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y., Wang Q.-M., Zheng J.-J., Xu L., Holmes E. C., Zhang Y.-Z., Nature 2020, 579, 265–269. - PMC - PubMed
    1. Fett C., DeDiego M. L., Regla-Nava J. A., Enjuanes L., Perlman S., J. Virol. 2013, 87, 6551–6559. - PMC - PubMed
    1. Kim E., Okada K., Kenniston T., Raj V. S., AlHajri M. M., Farag E. A. B. A., AlHajri F., Osterhaus A. D. M. E., Haagmans B. L., Gambotto A., Vaccine 2014, 32, 5975–5982. - PMC - PubMed
    1. Yang L.-T., Peng H., Zhu Z.-L., Li G., Huang Z.-T., Zhao Z.-X., Koup R. A., Bailer R. T., Wu C.-Y., Clin. Immunol. 2006, 120, 171–178. - PMC - PubMed
    1. Martin J. E., Louder M. K., Holman L. A., Gordon I. J., Enama M. E., Larkin B. D., Andrews C. A., Vogel L., Koup R. A., Roederer M., Bailer R. T., Gomez P. L., Nason M., Mascola J. R., Nabel G. J., Graham B. S., Vaccine 2008, 26, 6338–6343. - PMC - PubMed

MeSH terms